Andere talen Salarius Pharmaceuticals, Inc.

Aandelen

SLRX

US79400X3052

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,501 ^USD	-5,04%		+1,19%	-22,92%

25/03	Wall Street zal maandag licht lager openen in aanloop naar cijfers over huizenmarkt en inflatie	MT
25/03	Top premarket stijgers	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data	25/03
Top Premarket Gainers	25/03
North American Morning Briefing : Tech in Focus on -2-	25/03
Salarius: Q4 Earnings Snapshot	22/03
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	22/03
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	22/02
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	22/02
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders	16/01
Salarius Pharmaceuticals, Inc. Announces Update on Hematologic Cancer Phase 1/2 Clinical Trial Be Conducted At the University of Texas MD Anderson Cancer Center	03/01
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment	03/01
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12
North American Morning Briefing : Stock Futures -2-	16/11
Salarius: Q3 Earnings Snapshot	10/11
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program	07/11
Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program	07/11
Salarius: Q2 Earnings Snapshot	10-08-23
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10-08-23
Sector Update: Health Care Stocks Decline Thursday	10-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Salarius Pharmaceuticals, Inc.

Aandelen

SLRX

US79400X3052

Andere talen

Filters